This site is for US Health Care Professionals only
Tasigna - Treating patients with Ph+ CML since 2007

Save on TASIGNA

Novartis Universal Co-pay Card
Patients may be eligible for immediate co-pay savings on their next prescription of TASIGNA.
  • Eligible patients with private insurance may pay $0 per month
  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

To determine patient eligibility for the Novartis Oncology Universal Co-pay Program, call 1-877-577-7756 or visit Copay.NovartisOncology.com.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.

1 month free for patients new to TASIGNA

One Month Free Trial Voucher
Patients can get their first month of TASIGNA free

Patients who have been prescribed TASIGNA may be eligible to receive a free 1-month supply shipped directly to their home, which will allow them to start their treatment quickly.

No purchase of TASIGNA or any other product is required.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch ↗, or call 1-800-FDA-1088.

Print your 1 month FREE trial voucher

Ph+ CML-CP, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase; TKIs, tyrosine kinase inhibitors.

Important Safety Information for TASIGNA

BOXED WARNING: QT PROLONGATION AND SUDDEN DEATHS

  • TASIGNA prolongs the QT interval. Prior to TASIGNA administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, 7 days after initiation, and periodically thereafter, and following any dose adjustments
  • Sudden deaths have been reported in patients receiving TASIGNA. Do not administer TASIGNA to patients with hypokalemia, hypomagnesemia, or long QT syndrome

Indications

Adult and Pediatric Patients With Newly Diagnosed Ph+ CML-CP

TASIGNA is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).

Click or scroll for full Important Safety Information and Indications